Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2012

View Archived Issues

Health Canada approves line extension for Prevnar 13

Bioheart gains worldwide rights to adipose stem cell technology

Novel MAP kinase p38 alpha inhibitors synthesized at Amgen

BioCryst reports preclinical data on BCX-5191

Adeona Pharmaceuticals changes name

Arno Therapeutics and Invivis Pharmaceuticals sign licensing agreement

GSK withdraws indication extension application for Tyverb

German marketing collaboration signed for Vitaros

Novartis Vaccines and Diagnostics withdraws MAA for Fluad Pediatric

New aldose reductase inhibitors designed in U.S.

New GSNOR inhibitors and tachykinin NK3 receptor antagonists patented

Genetadi Biotech presents novel integrin alpha-V/beta-3 ligands

Takeda reports novel NF-kappa-B activation inhibitors

Japanese and Spanish university jointly develop new beta-amyloid production inhibitors

Novel candidate analgesics prepared at Pfizer

Chinese company divulges new GPR119 receptor agonists and DPP IV inhibitors

Collaborating U.S. universities identify new monoamine reuptake inhibitors

FDA accepts Uceris NDA

New beta-amyloid production inhibitors discovered at Bristol-Myers Squibb

UCB planning regulatory applications for Cimzia in new indication

Study reveals mode of action of influenza-inhibiting NME

New analgesic is potent and not addictive

BioMarin begins clinical testing of achondroplasia candidate

Ongoing phase III trials of NX-1207 show no safety concerns

Roche obtains Canadian approval for Zelboraf

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...